Live Feeds
● LIVE Updated 59m ago · 26 sources tracked

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Moderna and Merck's mRNA cancer vaccine, when combined with Merck's immunotherapy Keytruda, reduced the risk of melanoma death or recurrence by 42% in a late-stage trial. The vaccine is personalized and targets the deadliest form of skin cancer. This development could pave the way for a new era of personalized treatment. The trial's results met Wall Street expectations but triggered a 'sell-the-news reaction'.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (26)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna and Merck's mRNA cancer vaccine cut death, recurrence by 42%
  • ✓ The vaccine is personalized and targets the deadliest form of skin cancer, melanoma
  • ✓ The vaccine was used in combination with Merck's immunotherapy Keytruda
  • ✓ The trial's results met Wall Street expectations
🛡️ Source Corroboration: 26 independent reporting domains (85% confidence) ⏱ Read time: ~2 min

What changed

Moderna and Merck released top-line results from their late-stage trial, confirming the vaccine's efficacy in reducing melanoma death or recurrence risk.

Live updates

  1. Moderna and Merck's mRNA cancer vaccine cuts death, recurrence by 42%

    Moderna and Merck's mRNA cancer vaccine, when combined with Merck's immunotherapy Keytruda, reduced the risk of melanoma death or recurrence by 42% in a late-stage trial. The vaccine is personalized and targets the deadliest form of skin cancer. This development could pave the way for a new era of personalized treatment. The trial's results met Wall Street expectations but triggered a 'sell-the-news reaction'.

    Why it matters

    Melanoma is the deadliest form of skin cancer, and current treatments have limited success rates. Personalized mRNA vaccines have been a promising area of research in cancer treatment. The combination of this vaccine with immunotherapy Keytruda showed significant improvement in patient outcomes. The results of this trial could lead to new treatment options for melanoma patients.

    What is confirmed

    • Moderna and Merck's mRNA cancer vaccine cut death, recurrence by 42%
    • The vaccine is personalized and targets the deadliest form of skin cancer, melanoma
    • The vaccine was used in combination with Merck's immunotherapy Keytruda
    • The trial's results met Wall Street expectations

    What to watch next

    • Further details on the trial's results and data
    • FDA approval and potential market release of the vaccine
    • Long-term effects and survival data from the trial
    Sources used for this update (27)
    1. arstechnica.com — Ars Technica - Serving the Technologist since 1998. News, reviews, and ...
    2. www.statnews.com — STAT — Reporting from the frontiers of health and medicine
    3. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    4. time.com — How Trump’s Policies Are Testing Farmers’ Loyalty Ahead of Midterms
    5. WSJ — Moderna’s Shares Plummet After Cancer-Vaccine Data Shared on Social Media
    6. CNBC — Moderna shares plunge after leak of cancer vaccine data despite positive results
    7. Yahoo Finance — Moderna stock crashes as leaked melanoma data threatens its record August rally
    8. Reuters — Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
    9. CNN — Experimental mRNA vaccine cuts risk melanoma returns by 42%
    10. The New York Times — Cancer Vaccine Cuts the Risk of Melanoma Recurrence, Drug Makers Report
    11. Ars Technica — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    12. The Washington Post — Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
    confidence 85%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community